NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana (NASDAQ: NCNA) announced new clinical and preclinical data for NUC-3373 on Oct 14, 2025. Module 1 of the NuTide:303 study treated 12 heavily pre-treated advanced solid-tumor patients with NUC-3373 plus pembrolizumab. Highlights include a 100% reduction in tumor lesion size in a urothelial carcinoma patient who stayed on treatment >15 months, and an 81% reduction in target lesions in a metastatic melanoma patient who remains progression-free at 23 months. Complementary preclinical data (PLOS ONE) show NUC-3373 promotes DAMP release, boosts NK-cell activation, and enhances PD-1 blockade–mediated tumor cell death. The company says it maintains an anticipated cash runway into 2029.
NuCana (NASDAQ:NCNA) has announced its full compliance with all Nasdaq continued listing criteria, including the critical $1.00 minimum bid price requirement. The company has successfully resolved its previously disclosed Nasdaq listing concerns, with formal confirmation received on September 4, 2025.
Executive Chairman Andrew Kay highlighted that the company's current cash position, bolstered by ATM offering proceeds, is expected to fund operations into 2029. This extended runway will support multiple upcoming data readouts and key value-driving milestones in their cancer treatment development programs.
NuCana (Nasdaq: NCNA) announced its upcoming presentation at the ESMO Congress 2025 in Berlin, Germany, scheduled for October 17-21, 2025. The presentation will focus on research demonstrating synergy between NUC-7738 and PD-1 inhibition in renal cell cancer, using patient-derived organoids.
The poster presentation (Number: 1530P) will be delivered by H. Abdullah on Sunday, October 19, 2025, during the Investigational Immunotherapy session. The abstract will be published on the ESMO website on October 13, 2025, at 6:05 p.m. ET and in the ESMO Congress 2025 Abstract Book.
NuCana (NASDAQ: NCNA) has reported its Q2 2025 financial results and provided significant updates on its clinical development programs. The company has begun dosing patients in the expansion study of NUC-7738 combined with pembrolizumab for PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025. The expansion will add 28 patients, bringing the total treated population to 40.
Financially, NuCana has strengthened its position through an ATM offering and financing initiatives, raising $38.4 million in gross proceeds in 2025. The company reported cash and equivalents of £8.4 million as of June 30, 2025, with additional £19.0 million raised post-quarter. These actions have extended the company's cash runway into 2029. The quarter saw a net loss of £24.1 million, including a £12.6 million warrant revaluation loss.
NuCana (NASDAQ: NCNA) has announced a significant change in its American Depositary Shares (ADS) ratio, effective August 11, 2025. The ratio will change from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares.
This adjustment effectively functions as a 1-for-200 reverse ADS split. The change aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While shareholders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally.
The transition will be automatic for holders of uncertificated ADSs, while those holding certificated ADSs must surrender them to Citibank for exchange. Fractional ADSs will be sold, with proceeds distributed to affected holders.
NuCana (NASDAQ: NCNA) has successfully canceled all outstanding Series A Warrants that were originally issued during its May 2025 registered direct offering. The company raised the necessary capital through an at-the-market (ATM) offering to complete the cancellation of 59.5 million warrants for a payment of $3.6 million.
This strategic move, announced on June 27, 2025, eliminates all overhanging rights from the May 2025 offering, potentially providing more clarity to the company's capital structure.
NuCana (NASDAQ: NCNA) announced plans to implement a significant change in its American Depositary Shares (ADS) ratio. The company will modify the ratio from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025.
This change effectively functions as a 1-for-200 reverse ADS split. The move aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While holders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally, though this is not guaranteed.
NuCana (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on cancer treatments, has priced a $7 million registered direct offering of 10,845,985 American Depository Shares (ADSs) or pre-funded warrants. Each ADS or warrant is priced at $0.6454 and comes with two additional warrants: a Series A warrant to purchase one ADS at $0.8068 per share and a Series B warrant at $1.61 per share.
The proceeds will fund the company's drug discovery and development programs, along with general corporate purposes including working capital, investments, and potential acquisitions. The offering, managed by Laidlaw & Company as sole placement agent, is expected to close around May 7, 2025.
NuCana (NASDAQ: NCNA) has reported its Q4 and full-year 2024 financial results, highlighting progress in its anti-cancer drug development programs. The company's lead program, NUC-7738, showed promising results in combination with pembrolizumab, achieving disease control in 75% of patients with PD-1 inhibitor-resistant melanoma.
Financial highlights include cash position of £6.7 million as of December 31, 2024, with runway extended into Q3 2025. The company reported a reduced net loss of £19.0 million for 2024, compared to £27.6 million in 2023. Loss per share improved to £0.26 for 2024 from £0.53 in 2023.
Key 2025 milestones include initiating an expansion study of NUC-7738 with pembrolizumab for melanoma patients and seeking FDA guidance on pivotal study design. The company will also continue development of NUC-3373, which has shown positive results in combination studies.